LE外文电子书籍.pdfVIP

STUDY Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of Lupus Erythematosus Tamara Salam Housman, MD; Joseph L. Jorizzo, MD; Martha A. McCarty, MS, PA-C; Sarah E. Grummer; Alan B. Fleischer, Jr, MD; Paul G. Sutej, MD Background: Thalidomide is an anti-inflammatory agent ments of improvement listed in the clinic notes and were and an immunomodulator that inhibits the production categorized as “no response,” “partial response,” and “com- of tumor necrosis factor . It has shown promise as a treat- plete response.” Partial response was classified as either 75% ment option for the cutaneous manifestations of lupus or greater or less than 75% improvement. The incidence erythematosus (LE). of adverse effects including peripheral neuropathy was de- termined. Objective: To assess the degree of clinical response per subtype of cutaneous lupus, the duration of therapy be- Results: Of the 23 patients, 17 (74%) demonstrated com- fore documented clinical improvement, and the inci- plete resolution of the cutaneous manifestations of LE, dence of adverse effects, including peripheral neuropa- whereas 3 patients (13%) demonstrated 75% or greater thy, with low-dose thalidomide therapy at 100 mg daily partial improvement; 3 patients (13%) had less than 75% in the treatment of refractory cutaneous lesions of LE. partial clinical improvement; and 21 patients (91%) who